American Association for Cancer Research
Browse
- No file added yet -

Table S1 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions

Download (84.04 kB)
journal contribution
posted on 2023-03-30, 16:25 authored by Giovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, Justin J. Ellis, Jason G. Harb, Paolo Neviani, Shuzhen Wang, Ann-Kathrin Eisfeld, Christopher J. Walker, Bin Zhang, Klara Srutova, Carlo Gambacorti-Passerini, Gabriel Pineda, Catriona H. M. Jamieson, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Philippa C. May, Alistair G. Reid, Ramiro Garzon, Denis-Claude Roy, Moutuaata M. Moutuou, Martin Guimond, Peter Hokland, Michael W. Deininger, Garrett Fitzgerald, Christopher Harman, Francesco Dazzi, Dragana Milojkovic, Jane F. Apperley, Guido Marcucci, Jianfei Qi, Katerina Machova Polakova, Ying Zou, Xiaoxuan Fan, Maria R. Baer, Bruno Calabretta, Danilo Perrotti

Range values of controls for the indicated experiments

Funding

NIH

NCI

DOD

ACS

MSMT CZ

CRS

NSFC

Scholarship Council

History

ARTICLE ABSTRACT

Persistence of drug-resistant quiescent leukemic stem cells (LSC) and impaired natural killer (NK) cell immune response account for relapse of chronic myelogenous leukemia (CML). Inactivation of protein phosphatase 2A (PP2A) is essential for CML-quiescent LSC survival and NK cell antitumor activity. Here we show that MIR300 has antiproliferative and PP2A-activating functions that are dose dependently differentially induced by CCND2/CDK6 and SET inhibition, respectively. MIR300 is upregulated in CML LSCs and NK cells by bone marrow microenvironment (BMM) signals to induce quiescence and impair immune response, respectively. Conversely, BCR-ABL1 downregulates MIR300 in CML progenitors to prevent growth arrest and PP2A-mediated apoptosis. Quiescent LSCs escape apoptosis by upregulating TUG1 long noncoding RNA that uncouples and limits MIR300 function to cytostasis. Genetic and pharmacologic MIR300 modulation and/or PP2A-activating drug treatment restore NK cell activity, inhibit BMM-induced growth arrest, and selectively trigger LSC apoptosis in vitro and in patient-derived xenografts; hence, the importance of MIR300 and PP2A activity for CML development and therapy. Tumor-naïve microenvironment–induced MIR300 is the only tumor suppressor miRNA that induces CML LSC quiescence while inhibiting NK cell antitumor immune response, and CML LSC/progenitor cell apoptosis through its anti-proliferative and PP2A-activating functions, respectively. Thus, the importance of MIR300 and PP2A-activating drugs for formation/survival and eradication of drug-resistant CML LSCs, respectively.See related commentary by Broxmeyer, p. 13.This article is highlighted in the In This Issue feature, p. 5

Usage metrics

    Blood Cancer Discovery

    Categories

    Keywords

    cancer

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC